drug prices

House drug price negotiation plan could apply beyond Medicare
Draft plan would have government set prices based on those in other wealthy countries

Speaker Nancy Pelosi, D-Calif., has been heavily involved in House Democrats' drug price plan. A spokesman emphasized that it's still a work in progress. (Tom Williams/CQ Roll Call)

A comprehensive drug price bill being developed by House Democrats would give private insurers the benefit of government-negotiated prices, according to a summary of the measure obtained by CQ Roll Call.

Under the Democrats’ draft plan, the government would set prices based on what is paid in other wealthy countries, according to the summary. That is similar to how a proposal by the Trump administration would work.

Senate bill aims to protect taxpayers from costly drugs
Seeks to help Medicare control costs so premiums can remain stable

One proposed change to Medicare prescription drug benefit is to help the program control costs it absorbs to keep premiums stable. (CQ Roll Call file photo)

Congress this year could enact the biggest overhaul of Medicare’s prescription drug benefit since it was first established in 2003. If successful, seniors — and taxpayers — would be more insulated against the cost of the most expensive drugs. 

One proposed change is meant to help Medicare control the costs it absorbs so that the program’s premiums can remain stable despite increasing drug prices. Supporters of the drug program tout its low premiums, with the Trump administration and the private insurers who run Part D recently highlighting that average consumer premiums will fall in 2020.

Senate bill’s drug pricing provision raises industry alarms
Provision could force drugmakers to cut patient assistance for chemotherapy drugs

A mountain of pills, tablets, gelcaps and caplets, for pain medication. (File photo by Ian Wagreich, CQ Roll Call)

A little-noticed provision of the Senate Finance Committee drug price bill is alarming some doctors, with at least one group warning it could harm patients with fragile medical conditions.

The Community Oncology Alliance, an advocacy group for cancer doctors, is raising red flags about a provision it says could prompt drugmakers to cut patient assistance for pricey chemotherapy drugs, or shortchange doctors who buy them.

Finance advances drug price measure with tepid GOP support
Only six of the panel’s 15 Republicans voted to advance the measure

Senate Finance Chairman Sen. Chuck Grassley, R-Iowa, pushed back against criticism that the measure represented “price controls” (Bill Clark/CQ Roll Call file photo)

The Senate Finance Committee on Thursday approved, 19-9, a draft bill meant to reduce the cost of drugs in Medicare and Medicaid.

Only six of the panel’s 15 Republicans voted to advance the measure, joining all 13 Democrats. The most controversial amendments to the measure were rejected on mostly party-line votes.

Finance drug price bill faces GOP resistance before markup
Proposals target Medicare drug prices

Senate Finance Chairman Charles E. Grassley, R-Iowa, on Tuesday offered a details on a drug price bill. (Bill Clark/CQ Roll Call file photo)

The Senate Finance Committee on Tuesday outlined a long-anticipated drug price bill, but a planned Thursday markup may not go smoothly because of Republican discontent with the measure.

The bill is meant to slow the growth of Medicare’s prescription drug spending, limit cost-sharing for Medicare beneficiaries, and make it easier for state Medicaid programs to pay for expensive treatments, according to a summary.

Drug price transparency prompts fight among Democrats
Dispute is partly a turf battle between two committees who want to produce legislation on a high-profile issue

Consumer advocates clearly prefer a measure offered in the the Energy and Commerce Committee by Rep. Jan Schakowsky, D-Ill. (Bill Clark/CQ Roll Call file photo)

A dispute among Democrats over competing drug price transparency bills is complicating an issue that should have been one of the least controversial parts of the congressional effort to lower health care costs.

Two panels that oversee health care issues each approved measures this year to require drug companies to reveal information when they increase prices. While consumer advocates note drawbacks with both, they clearly prefer a measure from the Energy and Commerce Committee by Rep. Jan Schakowsky, D-Illinois, over a similar Ways and Means Committee bill.